SPRR2A and carcinoma: In our study, ttIL-12 treatment, compared with wtIL-12, induced higher IL-12 levels at the tumor sites and lower IL-12 levels in serum (Fig. 2e, Additional file 1: Figure S6A), which was accomplished by the tumor-anchoring effect of the CSV-targeting carcinoma homing peptide expressed by ttIL-12.